Generics 12

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Abiraterone manufacturers

12 products found

Filters

Filters

Filters , active

Country of origin : India

Clear all

12 products found

abiraterone

Tablets, film coated 250 mg, 500 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Chile , Turkey , Vietnam , Panama
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #22283

Manufacturer usually replies in 4 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19664

Manufacturer usually replies in 5 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18530

Manufacturer usually replies in 4 days

abiraterone

Tablets, film coated 250 mg, 500 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Algeria , Bahrain , Iran , Kuwait , Oman , Qatar , Saudi Arabia , United Arab Emirates , Vietnam
Available for
Licensing with supply
Comments
Indication: Prostate Cancer; Status: MA granted
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 11 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
GMP, WHO
Manufacturer #24869

Manufacturer usually replies in 3 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19588

Manufacturer usually replies in 7 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20087

Manufacturer usually replies in 8 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17691

Manufacturer usually replies in 7 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17417

Manufacturer usually replies in 6 days

abiraterone

Tablets 250 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA
Manufacturer #17753

Manufacturer usually replies in 10 days

abiraterone

Tablets 250 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17392

Manufacturer usually replies in 18 days

Abiraterone acetate Manufacturers

Abiraterone acetate is a medication used to treat prostate cancer. It is sold under the brand name Zytiga. More specifically it is used together with a corticosteroid for castration-resistant prostate cancer or mCRPC and metastatic high-risk metastatic castration-sensitive prostate cancer or mCSPC. It should be used in cases following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is an oral medication. Common side effects are such as tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include adrenocortical insufficiency and liver failure. Birth control is recommended in males whose partners can become pregnant. Supplied as abiraterone acetate it is converted in the body to abiraterone. Abiraterone acetate suppresses the production of androgens, specifically, it inhibits CYP17A1 and decreases the production of testosterone. Thus it prevents the effects of these hormones in prostate cancer. Abiraterone acetate was demonstrated in 1995 and gained approval for medical use in the United States and Europe in 2011. The World Health Organization listed in Essential Medicines, as the safest and most effective medicines needed in a health system. This medication is marketed widely throughout the world. Abiraterone acetate is used in combination with prednisone a corticosteroid, as a treatment for mCRPC (previously known as hormone-resistant or hormone-refractory prostate cancer). This is a kind of prostate cancer that does not respond to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone acetate has received approval from: Food and Drug Administration (FDA) (28 April 2011), European Medicines Agency (EMA) (23 September 2011), Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011) And Therapeutic Goods Administration (TGA) (1 March 2012) for this indication. it is covered by the Pharmaceutical Benefits Scheme In Australia, specifically when it is used to treat castration-resistant prostate cancer in combination with prednisone/prednisolone. The patient who is not currently receiving chemotherapy has been found either resistant or intolerant of docetaxel. The patient has a WHO performance status of <2. Besides his disease has not become progressive since treatment with PBS-subsidised abiraterone acetate has commenced. Contraindications include hypersensitivity to abiraterone acetate. Although documents state that it should not be taken by women. Specifically, who are pregnant or may become pregnant. There is no medical reason for any woman to take it. Pregnant women should not even touch the pills unless they are wearing gloves. Other cautions include: severe baseline hepatic impairment, mineralocorticoid excess, cardiovascular disease like heart failure and hypertension, uncorrected hypokalemia,

How Does Abiraterone acetate Work?

Abiraterone works by stopping the body’s production of a hormone called testosterone. It is usually done in a different way to other types of hormone therapy. Prostate cancer cells can't grow without testosterone, in most men. Even if they have spread to other parts of the body, they can't grow without it.

The Wholesale Price of Abiraterone acetate

The wholesale price of this pharmaceutical substance is around $50-65 USD per medicine. The price may vary and depends on the pharmacy you visit.

Sourcing Abiraterone Manufacturers and Abiraterone acetate Suppliers

Those who are looking for an easy and convenient way to source and order abiraterone may search online using Pipelinepharma's marketplace. Through our strict evaluation and quality control process, you are assured to find verified abiraterone manufacturers and suppliers.